INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 441m ago
House PTR41m ago
SEC 13F40m ago
Robinhood Chain40m ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.58B / 21S · 3 late79 trades$24.55M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04CFCheng Chi Fung0B / 42S42 trades$15.33M
  5. 05RARothblatt Martine A0B / 33S33 trades$5.50M
  6. 06RJRubinstein Julie0B / 32S32 trades$5.55M
  7. 07LBLeach Bryan0B / 30S30 trades$7.97M
  8. 08AOAtay Oguzhan0B / 30S30 trades$7.55M
  9. 09JDJenkins William D Jr0B / 30S30 trades$13.38M
  10. 10BSBiswas Sanjit0B / 28S28 trades$22.33M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  3. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  4. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  5. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  6. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  7. BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K
  8. SELLBCYCBICYCLE THERAPEUTICS PLCOct 2 – Oct 56 insiders$63K

Form 4 transactions

65,929 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
26
FR
Fenimore Christopher R.EVP Finance CFO
REGNREGENERON PHARMACEUTICALS, INC.
Tax withholding
F$4.03M
4,243 sh
Nov 2, 2026
Page 51 of 1649
← PrevNext →
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC Form 4

Evidence

26
LJ
Larosa Joseph JEVP General Counsel and Secret
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise
M$4.69M
12.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
BD
Bazzano DaraChief Accounting Officer
HOODRobinhood Markets, Inc.
Open-market sale · 10b5-1 plan
SELL$124K
1,473 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
BC
Bealmear Richard CraigChief Financial Officer
OKLOOklo Inc.
Open-market sale · 10b5-1 plan
SELL$427K
16.7K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
CM
Clark Benjamin M.EVP - Global Supply Chain
ECLECOLAB INC.
Tax withholding
F$1.14M
3,713 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
FS
Fambro SteveDirector, Co-CEO, 10% Owner
SEVAptera Motors Corp
Open-market sale
SELL$1,284
742 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
AL
Anthony Christopher LeeDirector, Co-CEO, 10% Owner
SEVAptera Motors Corp
Open-market sale
SELL$11K
6,145 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

26
KR
Krishnan Ram R.Executive Vice Pres & COO
EMREMERSON ELECTRIC CO
Tax withholding
F$4.47M
26.6K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

26
FS
Fambro SteveDirector, Co-CEO, 10% Owner
SEVAptera Motors Corp
Open-market sale
SELL$11K
6,146 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

25
LB
Leach BryanDirector, CEO AND PRESIDENT, 10% Owner
IBTAIbotta, Inc.
Open-market sale · 10b5-1 plan
SELL$48K
962 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

25
Saba Capital Management, L.P.10% Owner
GRXGabelli Healthcare & WellnessRx Trust
Open-market purchase
BUY$1,018
100 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

25
AJ
Armas Joseph JayPresident, Otis Americas
OTISOtis Worldwide Corp
Open-market sale
SELL$20K
260 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

25
AJ
Armas Joseph JayPresident, Otis Americas
OTISOtis Worldwide Corp
Open-market sale
SELL$45K
575 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

25
WL
Way T LawrenceDirector
CUBICustomers Bancorp, Inc.
Open-market sale
SELL$62K
723 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

25
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$84K
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

25
PW
Podbere Burt W.CHIEF FINANCIAL OFFICER
CRWDCrowdStrike Holdings, Inc.
Open-market sale
SELL$655K
2,590 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

25
WR
White Donnell RChief DEI Officer, SVP
HBANHUNTINGTON BANCSHARES INC /MD/
Open-market sale
SELL$48K
3,000 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

25
KL
Karsanbhai Surendralal LancaDirector, President & CEO
EMREMERSON ELECTRIC CO
Tax withholding
F$10.42M
62.1K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

25
MR
Miller Michael RobertExecutive Vice President
LCNBLCNB CORP
Open-market sale
SELL$36K
1,817 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

25
MM
Matsuda MasaruEVP, Chief Legal Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.37M
40.0K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

25
OS
Olschan Brian SDirector, President and COO
ACUACME UNITED CORP
Open-market sale
SELL$90K
1,258 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC Form 4

Evidence

24
DA
DM Trust Aggregator, LLC10% Owner
BROSDutch Bros Inc.
Open-market sale · 10b5-1 plan
SELL$252K
5,591 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
KT
Krasnow ToddDirector
SYMSymbotic Inc.
Open-market sale · 10b5-1 plan
SELL$31K
836 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
JC
Javitt Jonathan CDirector, CEO and Chairman
NRXPNRX Pharmaceuticals, Inc.
Grant or award
A—
150.0K sh
Jul 28, 2026Nov 4, 2026
traded Jul 28, 2026
+99dSEC Form 4

Evidence

24
FS
Fambro SteveDirector, Co-CEO, 10% Owner
SEVAptera Motors Corp
Grant or award
A—
17.6K sh
Dec 29, 2025Nov 4, 2026
traded Dec 29, 2025
+310dSEC Form 4

Evidence

24
SM
Skeete Bernard MChief Accounting Officer
VLTOVeralto Corp
Option exercise
M$112K
1,514 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
BT
Boersma TravisDirector, Executive Chairman of Board, 10% Owner
BROSDutch Bros Inc.
Open-market sale · 10b5-1 plan
SELL$252K
5,591 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
OJ
O Connor Kevin JDirector
PCORPROCORE TECHNOLOGIES, INC.
Open-market sale · 10b5-1 plan
SELL$106K
1,923 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
BP
Burnett PatrickEVP, Chief Medical Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$30K
943 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

24
PK
Phan KongChief Accounting Officer
MDBMongoDB, Inc.
Grant or award
A—
6,027 sh
Jun 12, 2026Nov 4, 2026
traded Jun 12, 2026
+145dSEC Form 4

Evidence

24
BB
Barker BrianDirector
ACUACME UNITED CORP
Option exercise
M$109K
5,000 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

24
OJ
O Connor Kevin JDirector
PCORPROCORE TECHNOLOGIES, INC.
Open-market sale · 10b5-1 plan
SELL$459K
7,582 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

24
AS
Abrams Michael SChief Financial Officer
NRXPNRX Pharmaceuticals, Inc.
Grant or award
A—
75.0K sh
Jul 28, 2026Nov 4, 2026
traded Jul 28, 2026
+99dSEC Form 4

Evidence

24
BB
Barker BrianDirector
ACUACME UNITED CORP
Tax withholding
F$109K
1,565 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

24
SL
Santiago Virgilio LiraChief Financial Officer
ATCXATLAS CRITICAL MINERALS Corp
Grant or award
A—
10.0K sh
Apr 7, 2026Nov 4, 2026
traded Apr 7, 2026
+211dSEC Form 4

Evidence

24
DR
Davies Benjamin R.CVP & Pres. Defense Systems
NOCNORTHROP GRUMMAN CORP /DE/
Tax withholding
F$156K
281 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

23
RC
Ring ChristineChief Legal Officer
NRIXNurix Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$158K
6,113 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

23
TB
Templeton Mark BDirector
ANETArista Networks, Inc.
Open-market sale · 10b5-1 plan
SELL$167K
1,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

23
TB
Templeton Mark BDirector
ANETArista Networks, Inc.
Open-market sale · 10b5-1 plan
SELL$150K
900 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

23
TB
Templeton Mark BDirector
ANETArista Networks, Inc.
Open-market sale · 10b5-1 plan
SELL$230K
1,400 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence